PDF(Pubmed)
Abstract：
(1) Background: BRAF mutations affect 4-5% of lung adenocarcinomas. This study aimed to analyze the clinicopathological features of lung carcinomas with BRAF mutations, focusing on V600E vs. non-V600E and the presence of co-mutations. (2) Methods: All BRAF-mutated lung carcinomas were retrieved from a molecular diagnostic unit (the reference unit for four different hospitals). The samples were analyzed using next-generation sequencing. Statistical analyses included log-rank tests for overall survival (OS) and progression-free survival (PFS). (3) Results: In total, 60 BRAF-mutated lung carcinomas were retrieved: 24 (40.0%) with V600E and 36 (60.0%) with non-V600E mutations, and 21 (35.0%) with other co-mutations and 39 (65.0%) with only BRAF mutations. Survival data were available for 54/60 (90.0%) cases. Targeted therapy was documented in 11 cases. Patients with V600E mutations exhibited a better prognosis than patients with non-V600E mutations (p = 0.008 for OS, p = 0.018 for PFS); this was confirmed in PFS (p = 0.036) when considering only patients who received no targeted therapy. Patients with co-mutations displayed no prognostic difference compared to patients carrying only BRAF mutations (p = 0.590 for OS, p = 0.938 for PFS). (4) Conclusions: BRAF-mutated lung carcinomas with V600E (40.0%) had a better prognosis than those without V600E. Concomitant co-mutations (35.0%) did not affect the prognosis.
摘要：
（1）背景：BRAF突变影响4-5％的肺腺癌。本研究旨在分析具有BRAF突变的肺癌的临床病理特征。专注于V600Evs.非V600E和共突变的存在。（2）方法：从分子诊断单元（四家不同医院的参考单元）检索所有BRAF突变的肺癌。使用下一代测序分析样品。统计分析包括总生存期(OS)和无进展生存期(PFS)的对数秩检验。（3）结果：总的来说，检索到60例BRAF突变的肺癌：24例（40.0％）具有V600E，36例（60.0％）具有非V600E突变，和21（35.0％）与其他共同突变和39（65.0％）只有BRAF突变。54/60（90.0％）病例的生存数据可用。11例患者有针对性治疗。V600E突变的患者比非V600E突变的患者预后更好（OS的p=0.008，PFS的p=0.018）；当仅考虑未接受靶向治疗的患者时，这在PFS中得到了证实（p=0.036）。与仅携带BRAF突变的患者相比，具有共同突变的患者没有预后差异（OS的p=0.590，PFS的p=0.938)。（4）结论：V600E的BRAF突变肺癌（40.0％）比无V600E的预后更好。伴随的共突变（35.0％）不影响预后。
